Strongyloidiasis risk factors

Revision as of 00:20, 30 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Strongyloidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Strongyloidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Strongyloidiasis risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Strongyloidiasis risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Strongyloidiasis risk factors

CDC on Strongyloidiasis risk factors

Strongyloidiasis risk factors in the news

Blogs on Strongyloidiasis risk factors

Directions to Hospitals Treating Strongyloidiasis

Risk calculators and risk factors for Strongyloidiasis risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Common risk factors in the development of strongyloidiasis include immunosuppressive therapies with corticosteroids and other medications, HTLV-1 infection, organ transplantation, immune reconstitution syndrome, hematologic malignancies (especially lymphoma), tuberculosis, and malnutrition.

Risk factors

Common risk factors in the development of strongyloidiasis include:[1][2]

References

  1. Evering T, Weiss LM (2006). "The immunology of parasite infections in immunocompromised hosts". Parasite Immunol. 28 (11): 549–65. doi:10.1111/j.1365-3024.2006.00886.x. PMC 3109637. PMID 17042927.
  2. Ostera G, Blum J (2016). "Strongyloidiasis: Risk and Healthcare Access for Latin American Immigrants Living in the United States". Curr Trop Med Rep. 3: 1–3. doi:10.1007/s40475-016-0065-3. PMC 4757600. PMID 26925367.

Template:WH Template:WS